Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 12-Month High - Here's What Happened

Key Points

• Kiniksa Pharmaceuticals International reached a new 52-week high of $34.46 during trading, with a closing price of $34.23.
• Analysts have raised their price targets for Kiniksa, with Jefferies Financial Group increasing theirs to $54.00 and a consensus price target now set at $41.17.
• The company reported quarterly earnings of $0.23 per share, exceeding estimates, and had revenue of $156.80 million for the quarter.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report)'s stock price reached a new 52-week high during mid-day trading on Monday . The company traded as high as $34.46 and last traded at $34.23, with a volume of 151068 shares traded. The stock had previously closed at $33.38.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on KNSA shares. Jefferies Financial Group increased their price target on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a research note on Tuesday, July 29th. Wall Street Zen upgraded shares of Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 2nd. Wells Fargo & Company upped their price target on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a research note on Wednesday, July 9th. Finally, Wedbush reiterated an "outperform" rating and issued a $36.00 price objective on shares of Kiniksa Pharmaceuticals International in a research note on Monday, July 21st. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $41.17.

Kiniksa Pharmaceuticals International Stock Up 1.2%

The company has a market cap of $2.50 billion, a PE ratio of 843.59 and a beta of 0.14. The stock has a 50-day moving average of $29.36 and a 200-day moving average of $25.08.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%. The business had revenue of $156.80 million for the quarter, compared to analyst estimates of $145.21 million. Research analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current year.

Insider Activity

In other news, CEO Sanj K. Patel sold 62,116 shares of the business's stock in a transaction that occurred on Wednesday, May 28th. The stock was sold at an average price of $27.33, for a total transaction of $1,697,630.28. Following the transaction, the chief executive officer directly owned 96,674 shares of the company's stock, valued at approximately $2,642,100.42. The trade was a 39.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Ross Moat sold 27,594 shares of Kiniksa Pharmaceuticals International stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $29.02, for a total transaction of $800,777.88. Following the completion of the sale, the insider owned 9,415 shares in the company, valued at approximately $273,223.30. This trade represents a 74.56% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 663,486 shares of company stock valued at $20,727,713. 53.48% of the stock is owned by corporate insiders.

Institutional Trading of Kiniksa Pharmaceuticals International

Several large investors have recently bought and sold shares of the company. Tower Research Capital LLC TRC lifted its position in Kiniksa Pharmaceuticals International by 1,539.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 25,275 shares of the company's stock valued at $699,000 after acquiring an additional 23,733 shares during the period. Rubric Capital Management LP increased its position in Kiniksa Pharmaceuticals International by 15.6% during the 2nd quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company's stock valued at $108,184,000 after buying an additional 526,567 shares in the last quarter. Lazard Asset Management LLC boosted its holdings in Kiniksa Pharmaceuticals International by 428.8% in the second quarter. Lazard Asset Management LLC now owns 15,181 shares of the company's stock worth $420,000 after acquiring an additional 12,310 shares in the last quarter. Engineers Gate Manager LP purchased a new stake in shares of Kiniksa Pharmaceuticals International in the second quarter worth $1,640,000. Finally, Cubist Systematic Strategies LLC increased its holdings in shares of Kiniksa Pharmaceuticals International by 213.2% during the second quarter. Cubist Systematic Strategies LLC now owns 657,475 shares of the company's stock valued at $18,192,000 after acquiring an additional 447,536 shares in the last quarter. 53.95% of the stock is owned by institutional investors.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.